Saiid Zarrabian - Kintara Therapeutics Director
Director
Mr. Saiid Zarrabian is President, Chief Executive Officer, Director of the Company. Mr. Zarrabian has served as our Interim President since January 1, 2018, our Interim Chief Executive Officer since November 3, 2017 and has served as a director since July 7, 2017. Since October 2016, Mr. Zarrabian has served as an advisor to Redline Capital Partners, S.A., a Luxemburg based investment firm. From 2012 to 2014 he served as Chairman and member of the Board of La Jolla Pharmaceutical Company during which time the company transitioned from an OTC listed company to a NASDAQ listed company. From 2012 to 2013 he served as President of the Protein Production Division of Intrexon Corporationrationration, a synthetic biology company. He has also previously served as CEO and member of the Board of Cyntellect, Inc., a stem cell processing and visualization Instrumentation company until its sale in 2012, as President and COO of Senomyx, Inc., a company focused on discovery and commercialization of new flavor ingredients, and as COO of Pharmacopeia, Inc., a former publiclytraded provider of combinatorial chemistry discovery services and compounds, where he also served as President COO of its MSI Division. In addition, Mr. Zarrabian has served on numerous private and public company boards, including at Immune Therapeutics, Inc., Exemplar Pharma, LLC, Ambit Biosciences Corporationrationration, eMolecules, Inc., and Penwest Pharmaceuticals CO. His other experience includes COO at Molecular Simulations, COO of Symbolics, Inc., and as RD Director at Computervision, Inc. Mr. Zarrabians scientific and business executive knowledge, and experience as our interim chief executive officer qualify him to serve on our Board of Directors. since 2018.
| Age | 64 |
| Tenure | 6 years |
| Phone | 858-350-4364 |
| Web | http://www.delmarpharma.com |
Kintara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (136.86) % which means that it has lost $136.86 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (316.72) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics' management efficiency ratios could be used to measure how well Kintara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Randolph Lewis | The Wendys Co | 64 | |
| Wesley Nichols | BJs Restaurants | 51 | |
| Steven Johnson | Rave Restaurant Group | 56 | |
| Peter Bassi | BJs Restaurants | 68 | |
| Peter Rothschild | The Wendys Co | 62 | |
| Mark McEachen | BJs Restaurants | 47 | |
| Arthur Winkleblack | The Wendys Co | 60 | |
| Noah Elbogen | BJs Restaurants | 35 | |
| Kenneth Gilbert | The Wendys Co | 67 | |
| Jeffrey Flug | Shake Shack | 58 | |
| William Hammett | Rave Restaurant Group | 71 | |
| Kristin Dolan | The Wendys Co | 51 | |
| Jenna Lyons | Shake Shack | 51 | |
| Anna Fieler | Shake Shack | 48 | |
| Matthew Peltz | The Wendys Co | 35 | |
| Ramon Phillips | Rave Restaurant Group | 84 | |
| Clinton Coleman | Rave Restaurant Group | 40 | |
| Brian Bares | Rave Restaurant Group | 43 | |
| Janet Hill | The Wendys Co | 68 | |
| Tristan Walker | Shake Shack | 35 | |
| Gabrielle Gordon | Pebblebrook Hotel Trust | N/A | |
Management Performance
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 |
Kintara Therapeutics Leadership Team
Elected by the shareholders, the Kintara Therapeutics' board of directors comprises two types of representatives: Kintara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kintara. The board's role is to monitor Kintara Therapeutics' management team and ensure that shareholders' interests are well served. Kintara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kintara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Praill, CFO and Principal Accounting Officer | ||
| John Bell, Independent Director | ||
| William Garner, Director | ||
| Erich Mohr, Independent Director | ||
| Saiid Zarrabian, Director | ||
| Robert Toth, Director | ||
| Dennis Brown, Chief Scientific Officer, Director | ||
| Jeffrey Bacha, President CEO, Director | ||
| Lynda Cranston, Independent Director | ||
| Robert Hoffman, Independent Director | ||
| Napoleone Ferrara, Director |
Kintara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kintara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 | |||
| Current Valuation | 13.09 M | |||
| Shares Outstanding | 11.46 M | |||
| Shares Owned By Insiders | 1.44 % | |||
| Shares Owned By Institutions | 12.46 % | |||
| Number Of Shares Shorted | 246.63 K | |||
| Price To Earning | (1.68) X | |||
| Price To Book | 3.26 X | |||
| EBITDA | (8.26 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kintara Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kintara Therapeutics' short interest history, or implied volatility extrapolated from Kintara Therapeutics options trading.
Pair Trading with Kintara Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kintara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kintara Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Chubb could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chubb when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chubb - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chubb to buy it.
The correlation of Chubb is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chubb moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chubb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chubb can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |